Legis Daily

Cameron’s Law

USA116th CongressHR-6238| House 
| Updated: 3/12/2020
Josh Gottheimer

Josh Gottheimer

Democratic Representative

New Jersey

Cosponsors (1)
Fred Upton (Republican)

Ways and Means Committee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Cameron's Law This bill increases the rate of the tax credit for clinical testing expenses for rare diseases or conditions from 25% to 50% (orphan drug tax credit). The bill also requires the Centers for Disease Control and Prevention to complete a study and report on enhancing and expanding the infrastructure to track the epidemiology of rare diseases or conditions.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Mar 12, 2020
Introduced in House
Mar 12, 2020
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • March 12, 2020
    Introduced in House


  • March 12, 2020
    Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Taxation

Business expensesCongressional oversightDrug safety, medical device, and laboratory regulationDrug therapyGovernment studies and investigationsIncome tax creditsMedical researchMedical tests and diagnostic methodsResearch and development

Cameron’s Law

USA116th CongressHR-6238| House 
| Updated: 3/12/2020
Cameron's Law This bill increases the rate of the tax credit for clinical testing expenses for rare diseases or conditions from 25% to 50% (orphan drug tax credit). The bill also requires the Centers for Disease Control and Prevention to complete a study and report on enhancing and expanding the infrastructure to track the epidemiology of rare diseases or conditions.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Mar 12, 2020
Introduced in House
Mar 12, 2020
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • March 12, 2020
    Introduced in House


  • March 12, 2020
    Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Josh Gottheimer

Josh Gottheimer

Democratic Representative

New Jersey

Cosponsors (1)
Fred Upton (Republican)

Ways and Means Committee, Energy and Commerce Committee

Taxation

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Business expensesCongressional oversightDrug safety, medical device, and laboratory regulationDrug therapyGovernment studies and investigationsIncome tax creditsMedical researchMedical tests and diagnostic methodsResearch and development